EOS Acquisition - Additional Information (Detail)
|
|
3 Months Ended |
|
|
|
|
Nov. 19, 2013
USD ($)
|
Jun. 30, 2016
USD ($)
|
Sep. 30, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
Nov. 19, 2013
EUR (€)
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Reduction in fair value of contingent purchase consideration liability |
|
$ 25,500,000
|
|
|
|
| Contingent purchase consideration |
|
|
$ 0
|
$ 24,661,000
|
|
| Ethical Oncology Science, S.p.A. |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Business acquisition cash payments made on acquisition |
$ 11,800,000
|
|
|
|
|
| Future maximum contingent milestone payments |
193,500,000
|
|
|
|
|
| Reduction in fair value of contingent purchase consideration liability |
|
$ 25,500,000
|
|
|
|
| Contingent purchase consideration |
|
|
$ 0
|
$ 24,700,000
|
|
| Ethical Oncology Science, S.p.A. | Regulatory and Sales Milestones |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Future maximum contingent milestone payments |
65,000,000
|
|
|
|
€ 115,000,000
|
| Future minimum potential contingent milestone payments |
0
|
|
|
|
€ 0
|
| Ethical Oncology Science, S.p.A. | Common Stock |
|
|
|
|
|
| Business Acquisition [Line Items] |
|
|
|
|
|
| Business acquisition, common stock issued at acquisition date |
$ 173,700,000
|
|
|
|
|